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Abstract
Purpose Trustworthy reporting of quadrivalent 
human papillomavirus (HPV) vaccine trials is the 
foundation for assessing the vaccine’s risks and 
benefits. However, several pivotal trial publications 
incompletely reported important methodological 
details and inaccurately described the formulation 
that the control arms received. Under the Restoring 
Invisible and Abandoned Trials initiative (RIAT), 
we aim to restore the public record regarding the 
content and rationale of the controls used in the 
trials.
Methods We assembled a cohort (five randomised 
controlled trials) described as placebo- controlled 
using clinical study reports (CSRs) obtained from 
the European Medicines Agency. We extracted 
the content and rationale for the choice of control 
used in each trial across six data sources: trial 
publications, register records, CSR synopses, CSR 
main bodies, protocols and informed consent 
forms.
Results Across data sources, the control 
was inconsistently reported as ‘placebo’-
containing aluminium adjuvant (sometimes 
with dose information). Amorphous aluminium 
hydroxyphosphate sulfate (AAHS) was not 
mentioned in any trial registry entry, but was 
mentioned in all publications and CSRs. In three 
of five trials, consent forms described the control 
as an ‘inactive’ substance. No rationale for the 
selection of the control was reported in any trial 
publication, register, consent form, CSR synopsis 
or protocol. Three trials reported the rationale for 
choice of control in CSRs: to preserve blinding and 
assess the safety of HPV virus- like particles as the 
‘safety profile of (AAHS) is well characterised’.
Conclusions The stated rationale of using AAHS 
control—to characterise the safety of the HPV 
virus- like particles—lacks clinical relevance. A non- 
placebo control may have obscured an accurate 
assessment of safety and the participant consent 
process of some trials raises ethical concerns.
Trial registration numbers NCT00092482, 
NCT00092521, NCT00092534, NCT00090220, 
NCT00090285.
INTRODUCTION
Randomised, placebo- controlled clinical trials are 
considered the gold standard for evaluating new 
vaccines. To evaluate the vaccine’s efficacy and 
safety, the manufacturer of quadrivalent human 
papillomavirus (qHPV) vaccine conducted multiple 
clinical trials including around 30 000 females and 
males. The vaccine was approved in 2006. Today, 
citing the vaccine’s efficacy and extensive safety 
profile, increasing HPV vaccine coverage is a high 
priority for many national governments and the 
WHO.1–3
Multiple trials of qHPV vaccine are reported 
as ‘placebo- controlled.’4–8 However, participants in 
the ‘placebo’ arms of these pivotal trials received 
an injection- containing amorphous aluminium 
hydroxyphosphate sulfate (AAHS), a proprietary 
adjuvant. AAHS is used in qHPV vaccine to boost 
immune response, but the rationale for adding 
AAHS to the ‘placebo’ is not reported in publications 
of these trials4–8 and is contrary to the advice of the 
public health bodies and regulators. The WHO, for 
example, recommends control recipients in trials 
testing an unlicensed, experimental vaccine receive 
either an inert substance or an approved effica-
cious vaccine.9 Similarly, the European Medicines 
Agency (EMA), which provides specific guidance on 
the clinical evaluation of vaccines, recommends the 
use of a licensed vaccine without an effect on the 
target disease if a placebo cannot be used.10
In addition, the efficacy and safety analyses 
of these five qHPV vaccine trials were conducted 
as if the trials were controlled with inert placebo 
when they were not. None of the key publications 
for these trials, which have been used to inform 
regulatory and health decision making, appear to 
discuss how AAHS- containing control could affect 
the interpretation of results.4–8
We consider the omission in journal articles, of 
any rationale for the selection of AAHS- containing 
control, to be a form of incomplete reporting of 
important methodological details, and believe the 
rationale must be reported. We also consider that 
the use of the term ‘placebo’ to describe an active 
comparator like AAHS inaccurately describes the 
formulation that the control arm participants 
received, and constitutes an important error that 
requires correction. If trial participants were told 
they could receive ‘placebo’ (widely defined as 
referring to an ‘inactive’11 12 or ‘inert’9 substance) 
without being informed of all non- inert contents 
of the control arm injection, this raises ethical 
questions about trial conduct as well.
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In January and February 2019, we publicly declared our 
intention to systematically correct the record for these trials13 14 
in accordance with the principles of the Restoring Invisible and 
Abandoned Trials (RIAT) initiative, of which some of us are 
founders.15 RIAT was founded with the intent of restoring the text 
of published biomedical articles where there is clear evidence of 
distortion or omission (as in the case of reporting bias or non- 
publication of clinical trials) and the original trial authors and/or 
sponsors fail to take any corrective action (thereby abandoning 
their responsibilities). While RIAT projects to date have focused 
on restoring trials through a reanalysis of all study data for a 
given trial,16–19 this project differs in its scope in two ways: first, 
we are focused on multiple trials in a single manuscript; second, 
this restoration is restricted to a specific aspect of the trials’ meth-
odology (the choice of control). We believe this ‘focused’ RIAT is 
important given the considerable implications that the choice of 
control has on the interpretation of trial results, and the fact that 
the problem is not confined to a single trial but rather spans a 
trial programme. Other criticisms of the reporting in qHPV trial 
publications (e.g., selective outcome reporting) have been made,20 
but we do not address those concerns here. Consistent with the 
RIAT approach, we wrote to the corresponding authors of all five 
publications as well as the sponsor requesting that they correct 
their publications. None contested our concerns nor indicated any 
intention to correct the record. As such, we consider these trials 
abandoned and hereby restore the record using data obtained 
under freedom of information requests to the EMA according to 
our prespecified protocol.21
Subjects and methods
Research design
Review of text describing the content and rationale for choice of 
control across published and unpublished data sources.
Data sources, searches and restoration sample
Since 2010, transparency policies at the EMA have allowed inde-
pendent investigators to obtain access to clinical study reports 
(CSRs) and other clinical data once protected as commercially 
confidential.22 CSRs are reports structured according to interna-
tional guidelines,23 written by sponsors and submitted to regu-
lators, generally as part of marketing authorisation applications, 
and provide far more detail than journal publications.24 In 2015, 
the EMA expanded its efforts to proactively publish CSRs to its 
website following regulatory decisions,25–27 a practice Health 
Canada also adopted as of 2019.28
The cohort of trials potentially eligible for restoration was 
all clinical trials of qHPV vaccine and nonavalent HPV vaccine 
for which we obtained CSRs from the EMA. These were received 
in response to a May 2014 freedom of information request. The 
process of obtaining CSRs has been previously described in an 
Index study29 and Analysis article.30 All trials evaluating qHPV 
vaccine and nonavalent HPV vaccine for which CSRs were 
obtained by 1 November 2018 were eligible for inclusion in this 
restoration.
Each CSR was reviewed by two independent assessors (with 
conflicts resolved by discussion or third party) for possible inclu-
sion against the following criterion: trial randomised control 
group participants to aluminium- containing adjuvant (as a 
control). We excluded trials which used an approved vaccine as 
the control.
Identification of matching trial publications
We aimed to identify the most impactful, company- authored 
trial publication for all trials in our sample using the following 
approach:
1. We identified the NCT number for each trial by searching for the 
trial ID, obtained from the CSR, on  ClinicalTrials. gov. We then 
compared trial characteristics (study population, intervention, 
comparator, name of primary outcome measure(s) and number 
of participants) with the CSR and a published index of HPV 
vaccine trial programme29 to confirm that the correct NCT 
record was identified.
2. From the  ClinicalTrials. gov registry entry for each trial, we 
recorded all publications (in all categories) listed under the 
‘Study Details’ tab.
3. Using the DOI of these publications, we identified the most 
cited publication of each trial using the Scopus database 
and obtained the article’s full- text PDF and supplementary 
material.
This process was carried out by two independent reviewers with 
discrepancies resolved by discussion or third- party consultation.
Determination of under-reporting and misreporting
For each trial using a concurrent aluminium- containing adju-
vant as a control, we reviewed the publication to determine the 
potential presence of under- reporting of the rationale for using 
such a control and misreporting of the control intervention (i.e., 
describing the control as ‘placebo’).
Data extraction
For each trial using six data sources (CSR synopsis, CSR main 
body, trial protocol, informed consent form, trial publication and 
trial register entry), we recorded (1) the phrases used to describe 
the comparator to qHPV vaccine; (2) the rationale for using 
aluminum- containing adjuvant as a control, if present and (3) all 
listed contents (ingredients) of formulation received by interven-
tion and control arms.
To enable an exhaustive list of all descriptions of the compar-
ator across all document types, especially CSRs which were often 
thousands of pages long, we searched for the terms placebo, 
control, comparator, alum, AAHS, adjuvant and MAA (Merck 
Aluminum Adjuvant). We categorised the verbatim phrases into 
three broad categories: phrases that described a placebo (with no 
mention of adjuvant), phrases that described a placebo containing 
adjuvant and phrases describing a placebo containing adjuvant as 
well as adjuvant dose information. We recorded the frequency of 
terms used to describe the formulation of the control arm and its 
ingredients, by data source.
Extractions were independently carried out by two assessors. 
There were no discrepancies, and a consolidated analysis data set 
was created.
Results
We obtained 14 trials from the EMA (eight qHPV vaccine, six 
nonavalent HPV vaccine), of which five met our prespecified 
inclusion criteria (V501-012, V501-013, V501-015, V501-019 and 
V501-020; figure 1). All included trials compared qHPV vaccine 
to aluminium- containing adjuvant. Corresponding register and 
publication information for each trial are listed in table 1.
Describing the control arm
There was heterogeneity in the verbatim phrases used to describe 
the control arm across all trials and types of documents (table 2).
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Figure 1 Summary of Trial Search. CSR, clinical study reports; EMA, 
European Medicines Agency; HPV, human papillomavirus.
Table 1 Characteristics of trials being restored
Trial ID/name ClinicalTrials.gov registration # Most cited trial publication Participants enrolled* Number of citations†
V501-012 ‘FUTURE 1’ NCT00092482 Garland et al7 3882 women, aged 16–24 32
V501-013 ‘FUTURE 1’ NCT00092521 Garland et al8 5455 women, aged 16–24 1312
V501-015 ‘FUTURE 2’ NCT00092534 FUTURE II Study Group4 12167 women, aged 15–26 1440
V501-019 ‘FUTURE 3’ NCT00090220 Muñoz et al5 3819 women, aged 21–46 318
V501-020 NCT00090285 Giuliano et al6 4065 men, aged 15–27 593
*Details taken from the clinical study report.
†Citation count from SCOPUS database as on 14 December 2018.
The publication abstracts and register entries for four trials only 
referred to the control arm as ‘placebo’ or ‘matching placebo’ (Garland 
et al8/NCT00092521, FUTURE II Study Group4/NCT00092534, 
Muñoz et al5/NCT00090220, Giuliano et al6/NCT00090285). The 
publication abstract and register entry for one trial (Garland et 
al7/NCT00092482) did not mention the existence of a control arm.
The informed consent forms for two trials (V501-019 and 
V501-020) did not provide participants with any information 
regarding the contents of the control arm. The informed consent 
forms for three trials (V501-012, V501-013 and V501-013) 
informed participants that they may be exposed to an ‘inactive 
solution (containing aluminium 225 mcg/dose)’.
The CSRs of all trials described the control arm as a ‘place-
bo’-containing 225 mcg of aluminium. While all CSRs stated the 
type of aluminium adjuvant (AAHS), the information was not 
reported in a consistent location (i.e., CSR synopsis, main body and 
protocol). A summary of reported ingredients, by data source, is 
presented in table 3.
We assessed the frequency of terms used to describe the control 
for the trial with the most highly cited publication in our study 
(V501-015). In the publication, the control was referred to as a 
placebo (with no mention of adjuvant) 67 times and one time as 
a placebo with adjuvant.4 In the CSR, the control was referred to 
as a placebo 1450 times versus 326 times as placebo with adju-
vant, and across six informed consent forms (US and international 
versions of the main consent form, child assent form and preg-
nancy consent addendum), 54 versus 2, respectively. Finally, in 
the register entry, the control was referred to as a placebo 50 times 
versus 0 times as a placebo with adjuvant.
Rationale for aluminium-containing control
The rationale for the selection of an AAHS- containing control 
was reported in the CSR of three trials (V501-012, V501-013 
and V501-015). No rationale was provided in any document 
for two trials (V501-019 and V501-020). In all five trials, the 
protocol, publication, register entry, informed consent form and 
CSR synopsis did not contain a rationale for the selection of the 
control (table 4).
The three studies that reported a rationale for the selection 
of an AAHS- containing control provided identical reasons: (1) 
to preserve blinding and (2) to assess the safety of HPV virus- 
like particles given that the ‘safety profile of (AAHS) is well 
characterised’.
Discussion
On its website, qHPV vaccine’s sponsor defines a placebo as ‘an 
inactive pill, liquid, or powder that has no treatment value’.11 This 
definition is consistent with the decades old notion of placebos 
as pharmacologically inert substances used to obtain unbiased 
assessments in experimental research.31
The five pivotal trials of qHPV vaccine that were the subject 
of this restoration used a control with aluminum- containing adju-
vant. This was stated in the journal publications of all trials. But 
contrary to what the original investigators reported, the trials 
were not placebo- controlled. The inclusion of AAHS in the control 
arm means that the control should not be reported as a placebo 
since AAHS is not inactive. While the original FDA- approved 
prescribing information in 2006 reported the AAHS- containing 
control as ‘placebo’, this was updated in September 2008, and 
all such references were removed and replaced with ‘AAHS 
control’.32–34
Inaccurate use of the term placebo is not confined to qHPV 
vaccine trials. As no regulations govern placebo composition, 
researchers have documented a diversity in what gets labelled a 
placebo in research, and that depending on the experimental arm, 
some so- called placebos may have effects that influence study 
outcomes.35
With respect to adjuvants in vaccines, the FDA has noted 
that ‘adjuvants have their own pharmacologic activity, which 
may affect both the immunogenicity and the safety of vaccines. 
Adverse reactions may include local reactions such as pain, 
swelling, injection site necrosis, and granulomas. Systemic reac-
tions may include nausea, fever, arthritis, as well as potential 
immunotoxic reactions. Unexpected, rare events may also occur’.36
The FDA has also stated that ‘the evaluation of safety of an 
adjuvanted vaccine needs to include special safety consider-
ations’, which may include data ‘derived by comparing the adju-
vanted vaccine to a placebo or the unadjuvanted vaccine antigen, 
if feasible’.36 The extent to which the evaluation of qHPV vaccine 
included such special safety considerations is debatable given the 
presence of adjuvant in the control.
The implications of AAHS controlled trials on an accurate 
assessment of the safety and efficacy of qHPV are important. It 
is possible that the presence of AAHS in both arms of the trials 
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Table 2 Phrases used to describe the control arm (proportion of trials)
Phrases used
ICF CSR Register Publication
Synopsis Main body Protocol Abstract Full text
Placebo 5/5 5/5 5/5 5/5 4/5 4/5 5/5
  ‘Placebo’ or ‘matching placebo’ 5/5 5/5 5/5 5/5 4/5 4/5 5/5
  ‘Placebo (which is a dose that contains no active ingredients)’ 4/5 0/5 0/5 0/5 0/5 0/5 0/5
  ‘Placebo … an inactive substance’ or ‘placebo … an inactive 
solution’
3/5 0/5 0/5 0/5 0/5 0/5 0/5
  ‘Placebo HPV Vaccine’ 3/5 0/5 0/5 0/5 0/5 0/5 0/5
Placebo with adjuvant 0/5 1/5 5/5 4/5 0/5 0/5 5/5
  ‘Placebo with adjuvant’ 0/5 0/5 2/5 0/5 0/5 0/5 0/5
  ‘Aluminum adjuvant placebo’ or ‘Alum- placebo’ or 
‘aluminum- placebo’ or ‘aluminum- containing placebo’ or 
‘visually indistinguishable aluminum- (or ‘AAHS’)containing 
placebo’ or ‘matched aluminum- placebo’ or ‘placebo 
(aluminum adjuvant)’
0/5 1/5 4/5 4/5 0/5 0/5 5/5
Placebo with adjuvant and dose 3/5 3/5 3/5 5/5 0/5 0/5 0/5
  ‘Placebo’-containing 225 ug of aluminium adjuvant 0/5 2/5 1/5 4/5 0/5 0/5 0/5
  ‘Placebo’ or ‘matched placebo’-containing Merck standard 
aluminium diluent (225 mcg alum), with or without mention 
of normal saline
0/5 1/5 0/5 2/5 0/5 0/5 0/5
  ‘Placebo’-containing 225 mcg of aluminium as AAHS, with or 
without mention of normal saline
0/5 1/5 2/5 0/5 0/5 0/5 0/5
  ‘Inactive solution (containing aluminium 225 mcg/dose)’ 3/5 0/5 0/5 0/5 0/5 0/5 0/5
Normal saline = USP (NaCl 0.9%).
AAHS, amorphous aluminum hydroxyphosphate sulfate; CSR, clinical study report; ICF, informed consent form.
Table 3 Ingredients of control arm, by trial document type
Trial Clinical study report Informed consent form Register Publication
V501-012 225 mcg of aluminium as AAHS 
in normal saline
Inactive solution (containing aluminium 225 
mcg/dose)
Control intervention not 
listed
Aluminium- containing 
placebo
V501-013 225 mcg of aluminium as AAHS 
in normal saline
Inactive solution (containing aluminium 225 
mcg/dose)
No ingredients listed; only 
states ‘placebo’
Aluminium- containing 
placebo
V501-015 225 mcg of aluminium as AAHS 
in normal saline
Inactive solution (containing aluminium 225 
mcg/dose)
No ingredients listed; only 
states ‘placebo’
Aluminium- containing 
placebo
V501-019 Merck standard aluminium 
diluent (225 mcg alum) in 
normal saline
No ingredients listed. Only states: ‘The HPV 
vaccine placebo contains no active vaccine’
No ingredients listed; only 
states ‘placebo’
Aluminium- containing 
placebo
V501-020 225 mcg of aluminium as AAHS 
in normal saline
No ingredients listed. Only states: ‘placebo, 
an injection that looks the same as the 
vaccine but has no active ingredient’
No ingredients listed; only 
states ‘placebo’
AAHS- containing 
placebo
Normal saline = USP (NaCl 0.9%).
AAHS, amorphous aluminum hydroxyphosphate sulfate.
masked AAHS’s reactogenic potential thereby obscuring any 
differential rates in harms, leading to an underestimate in harms. 
The qHPV vaccine trial results are consistent with these state-
ments. Across the five trials using AAHS in the control, the abso-
lute risk of injection- site adverse events was only 6%–13% higher 
in qHPV vaccine patients. By contrast, in study V501-018, which 
used a control lacking AAHS, the absolute risk increase was 25% 
(table  5). It is also possible that AAHS’s stimulating properties 
(which to our knowledge have never been studied on their own) 
provoked an immune response which may have been protective 
against endpoints studied in the trial, thereby leading to an under-
estimation of the effectiveness of qHPV vaccine. Because all the 
five trials lacked a true inert comparator arm, the trial data cannot 
resolve these questions.
It is not clear whether other trials can establish qHPV 
vaccine’s true safety and efficacy profile. The FDA instructed the 
sponsor to conduct a safety study with a control not containing 
aluminium, according to the company’s submission to Japanese 
regulators,37 and the CSR for trial V501-018 states that it was the 
only qHPV vaccine trial to do this. In contrast to other studies, 
the FDA medical officer who reviewed the sponsor’s marketing 
application referred to this trial’s control as a ‘true placebo’.38 
However, V501-018’s short follow- up of control arm participants 
(30 months), small sample (597 receiving control) and younger 
age relative to other trials makes it inadequate to resolve safety 
questions.
Our study raises serious questions about the ethics of consent 
in the trials. The informed consent forms for the trials described 
the placebo as an ‘inactive solution’ and ‘a dose that contains no 
active ingredients’. This likely misled many trial participants who 
would have reasonably expected the control did not contain a 
pharmacologically active adjuvant.
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Table 4 Rationale for aluminium- containing control (verbatim quotes)
Trial
Publications, registers, study 
protocols, ICFs, and CSR synopses Clinical study reports (CSR main body)
V501-012 None provided ‘Aluminum adjuvant was chosen as the appropriate control for the qHPV vaccine for the 
following reasons:
1. The inclusion of aluminum adjuvant in both vaccine and placebo preserved the blinding of 
the study because it allowed the vaccine and placebo to be visually indistinguishable; and
2. The safety profile of Merck’s aluminum adjuvant is well characterised. On the other hand, 
the safety profile of the HPV 6, 11, 16 and 18 L1 VLPs required further evaluation in 
humans. By using placebo that contained a dose of aluminum adjuvant that was identical 
to the dose included in the qHPV vaccine, it was possible to assess the safety profile 
attributable to the HPV 6, 11, 16 and 18 L1 VLP component of the vaccine.’
V501-013 None provided
V501-015 None provided
V501-019 None provided None provided
V501-020 None provided None provided
Normal saline = USP (NaCl 0.9%).
CSR, clinical study report; ICF, informed consent form; qHPV, quadrivalent human papillomavirus; VLP, virus- like particle.
Table 5 Injection- site adverse experiences between Gardasil and 
control arms
Trial Gardasil Control Difference Source
V501-012 87.9% 78.6% (with AAHS) 9.3% CSR p.33
V501-013 88.0% 79.8% (with AAHS) 8.2% CSR p.13
V501-015* 84.4% 77.9% (with AAHS) 6.5% Publication 
table 4
V501-019 76.7% 64.2% (with AAHS) 12.5% CSR p.566
V501-020 60.1% 53.7% (with AAHS) 6.4% CSR p.348
V501-018 75.3% 50.0% (without AAHS) 25.3% CSR p.33
*The CSR for V501-015 reports injection- site adverse experiences as 8.8% 
(qHPV) versus 7.6% (control), but these figures are likely an underestimate as 
injection- site adverse experiences were only collected for participants in the 
Non- Serious Adverse Experience Substudy, and data for this subpopulation 
were reported in the publication but not CSR.
AAHS, amorphous aluminium hydroxyphosphate sulfate; CSR, clinical study 
reports.
Our restoration makes public, for the first time, the sponsor’s 
rationale for using AAHS as a control. The manufacturer gave two 
reasons: first, to ensure that the control was not visually distin-
guishable, and second, to assess the safety profile of the HPV 
virus- like particles as the ‘safety profile of Merck’s aluminium 
adjuvant is well characterised’.
The fact that the qHPV vaccine and nonavalent HPV vaccine 
clinical trial programme included two randomised, double- blind 
trials that did not use an AAHS- containing control demonstrates 
that there was no necessity to use AAHS to maintain blinding. In 
these trials (V501-018 and V503-006), unblinded study personnel 
who were otherwise not involved in the study prepared and 
administered injections.
Second, the safety profile of AAHS is not well characterised. 
We are unaware of any randomised trial directly evaluating AAHS 
against placebo; a network meta- analysis is underway that aims 
to use extant randomised controlled trial (RCT) data to determine 
the safety profile of the AAHS component of qHPV vaccine.39 
Moreover, while other vaccines contain AAHS (e.g., Recombivax 
and VAQTA), such vaccines cannot be used to characterise AAHS 
safety as ‘it cannot be assumed that an adjuvant that is safe in one 
vaccine with a given antigen will be safe when added to another 
vaccine’.40 The unknown consequences of aluminum- containing 
adjuvants, more generally, is concerning. A Cochrane review is 
currently underway to determine whether any RCTs exist which 
evaluated the effects of aluminium adjuvants compared with 
placebo or no intervention.41
Finally, the stated rationale of using AAHS control, to char-
acterise the safety of the HPV virus- like particles, lacks clinical 
relevance. The clinically relevant question is what are the effects 
(benefits and harms) of qHPV vaccine—the whole product, not one 
of its components.
As crucial documents written before trials commence, it is 
concerning that study protocols did not include a rationale for 
the use of AAHS control. Protocols for V501-015, V501-019 and 
V501-020 stated: ‘To provide an appropriate control for the Quad-
rivalent HPV (Types 6, 11, 16, 18) L1 VLP Vaccine, the placebo 
used in this study will be Merck standard aluminum diluent 
(225 µg alum) in normal saline, USP (NaCl 0.9%)’. But the docu-
ments did not explain what made the adjuvant ‘appropriate’. We 
were also concerned that  ClinicalTrials. gov entries described the 
control with a single word (‘placebo’, not even mentioning AAHS), 
and in one case did not even list the control.
The Consolidated Standards of Reporting Trials (CONSORT) 
guidelines for reporting RCTs call for study interventions for each 
group to be described ‘with sufficient details to allow replication, 
including how and when they were actually administered’.42 We 
think CONSORT should also ask investigators to document their 
rationale for selecting these interventions, particularly the choice 
of control. Such reporting would allow for more transparency and 
a more informed discussion around the appropriateness of chosen 
controls, and is consistent with regulatory advice to industry 
that ‘the choice of control group is always a critical decision in 
designing a clinical trial’.43
Limitations
Across all study documents, the only ingredients we found 
listed in the control were AAHS and normal saline (NaCl 0.9%). 
However, there may have been other ingredients. According to 
qHPV vaccine’s prescribing information, each dose of vaccine 
contains ‘9.56 mg of sodium chloride, 0.78 mg of L- histidine, 50 
mcg of polysorbate 80, 35 mcg of sodium borate, <7 mcg yeast 
protein/dose and water’, in addition to AAHS and HPV virus- like 
particles.32–34 To test HPV virus- like particles, as the manufacturer 
stated was its intention in using an AAHS control, the control 
would logically have also included these other ingredients in addi-
tion to AAHS. We recommend that reports of trials (across publi-
cations, protocols, CSRs and registers) should contain a complete 
list of ingredients of all trial arms (if necessary, in supplementary 
materials when space limitations apply).
Our study may not represent a complete list of qHPV vaccine 
trial publications that under- report and misreport the control. 
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In our screening, we identified a trial (V501-005) with identical 
problems to the trials included in this restoration; however, this 
trial was excluded from our analysis as it reported on the use 
of a monovalent experimental HPV vaccine which was never 
licensed.44
Conclusions
The sponsor’s stated rationale of using AAHS control in qHPV 
vaccine trials—to characterise the safety of the HPV virus- like 
particles—lacks clinical relevance, as the clinically relevant issue 
is to characterise the safety profile of the whole qHPV vaccine. 
The non- placebo control used in qHPV vaccine trials may have 
obscured an accurate assessment of safety of qHPV vaccine 
and the participant consent process of some trials raises ethical 
concerns.
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